Abstract

In this study we explored the efficacy of combining low dose photodynamic therapy using a porphyrin photosensitiser and dactinomycin, a commonly used chemotherapeutic agent. The studies were carried out on compressed collagen 3D constructs of two human ovarian cancer cell lines (SKOV3 and HEY) versus their monolayer counterparts. An amphiphilc photosensitiser was employed, disulfonated tetraphenylporphine, which is not a substrate for ABC efflux transporters that can mediate drug resistance. The combination treatment was shown to be effective in both monolayer and 3D constructs of both cell lines, causing a significant and synergistic reduction in cell viability. Compared to dactinomycin alone or PDT alone, higher cell kill was found using 2D monolayer culture vs. 3D culture for the same doses. In 3D culture, the combination therapy resulted in 10 and 22 times higher cell kill in SKOV3 and HEY cells at the highest light dose compared to dactinomycin monotherapy, and 2.2 and 5.5 times higher cell kill than PDT alone. The combination of low dose PDT and dactinomycin appears to be a promising way to repurpose dactinomycin and widen its therapeutic applications.

Highlights

  • Photodynamic therapy is a minimally invasive modality for the treatment of solid tumours and certain non-cancerous lesions that relies on photoactivation of a photosensitising drug

  • The results showed that combining electroporation and photodynamic therapy to co-deliver the drugs led to a significant decrease in the viability of the ovarian cancer cells in a short time and enhanced the cell killing [66]

  • In this study we examined the efficacy of low dose photodynamic therapy in combination with dactinomycin as a chemotherapeutic drug in two human ovarian cancer cell lines, SKOV3 and HEY

Read more

Summary

Introduction

Photodynamic therapy is a minimally invasive modality for the treatment of solid tumours and certain non-cancerous lesions that relies on photoactivation of a photosensitising drug. The combination of chemotherapy or immunomodulation approach and photodynamic therapy (PDT) has been intensively investigated for the treatment of various types of cancers [1,2,3,4,5,6,7,8]. The rationale for the combination therapy approach is that the two modalities could be effective against different tumour sites thereby ensuring more effective treatment. PDT can aid delivery of the chemotherapeutic agents to the optimum sites in the tumour [9]. In addition to enhanced tumour destruction, it may be possible to use a lower dose of the chemotherapeutic agent, thereby limiting any systemic toxicity

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call